An encouraging 81.1% disease-free survival rate is highlighting the potential of Immutep Limited (ASX: IMM) as the Australian biotechnology company advances its next phase of cancer immunotherapy development. With promising clinical results, renewed manufacturing initiatives and a diversified drug pipeline, Immutep is building a clearer pathway towards future clinical and commercial milestones.
Key numbers
- 81.1%: 12-month disease-free survival in the Phase II EFTISARC-NEO trial.
- 94.1%: 12-month local recurrence-free survival in the same study.
- 86.2%: 12-month distant metastasis-free survival.
- $48.50 million: Cash and term deposits at 30 September 2026.
- $19.13 million: September-quarter operating cash outflow, down from approximately $38.9 million in the preceding quarter.
The latest development
Immutep's 18 November 2026 update highlights encouraging progress across its immunotherapy pipeline, particularly its lead treatment, eftilagimod alfa, known as efti.
The experimental therapy is designed to activate the immune system and strengthen its response against cancer.
Recent Phase II EFTISARC-NEO findings demonstrated 81.1% disease-free survival after 12 months among patients with resectable soft tissue sarcoma receiving efti alongside Keytruda and radiotherapy before surgery.
The study also reported 94.1% local recurrence-free survival and 86.2% distant metastasis-free survival.
These results reinforce the potential of efti-based combination treatments in cancers where preventing recurrence remains a major clinical challenge.
While the study involved 38 evaluable patients without a randomised control group, the findings provide a promising foundation for further clinical investigation.
Additional analyses are scheduled for presentation on 19 November 2026.
What stands out to us
One of Immutep's most encouraging developments is its ability to identify new opportunities for efti following the discontinuation of the TACTI-004 Phase III lung cancer trial in March 2026.
Rather than abandoning its lead therapy, the company has redirected resources towards indications supported by encouraging clinical evidence.
An investigation into the unsuccessful trial identified structural differences between efti manufactured at 2,000-litre scale and material produced at 200-litre scale for earlier studies.
These findings may provide useful direction for future manufacturing improvements, although a connection to the trial outcome has not been established.
Immutep has commissioned another 200-litre manufacturing run to support its next development phase.
The company is also demonstrating greater financial discipline.
September-quarter operating cash outflow declined significantly to $19.13 million, compared with approximately $38.9 million in the preceding quarter.
Management expects reduced expenditure to extend its funding runway into the first half of 2028.
Although additional capital may eventually be required, this improved cost position gives Immutep greater flexibility to pursue its highest-priority clinical programmes.
What the company is doing now
Immutep is concentrating efti development on selected head and neck cancer patients and soft tissue sarcoma, with new clinical trials targeted for the second half of 2027.
The company is also progressing IMP761, an experimental immunotherapy targeting autoimmune diseases.
Recent Phase I results demonstrated statistically significant, exposure-dependent suppression of T-cell-driven immune responses in healthy volunteers.
This development creates a second potential commercial opportunity beyond oncology.
If subsequent studies demonstrate meaningful benefits in patients, IMP761 could strengthen Immutep's pharmaceutical partnering prospects and broaden the potential value of its intellectual property.
Insight: Is Immutep Building a Stronger Foundation for Long-Term Growth?
We believe Immutep's renewed development strategy offers a credible opportunity to rebuild momentum. The encouraging sarcoma results support continued investigation of efti, while IMP761 provides an additional pathway towards commercial value. Importantly, the company's greater spending discipline could strengthen its ability to advance these programmes. Clinical uncertainty and manufacturing challenges remain, but its diversified pipeline offers several opportunities to generate meaningful evidence. We see the strongest potential in successful controlled trials, reproducible manufacturing and partnerships that could accelerate development while reducing future funding requirements.
What happens next?
Immutep's annual general meeting on 27 November 2026 is expected to provide further insight into its manufacturing investigation and development priorities.
Final overall survival data from the TACTI-003 head and neck cancer study are scheduled for presentation on 14 December 2026, followed by additional IMP761 milestones in 2027.
These developments could help establish whether Immutep's encouraging clinical findings translate into a stronger competitive position and greater commercial potential.
For shareholders, the combination of promising survival results, an expanding immunotherapy pipeline and improving expenditure control provides a constructive foundation for the company's next stage of development.